Beckman Coulter Announces Test to Help Assess Cardiac Risk and Other Diseases.
Business Editors and Health/Medical Writers
FULLERTON, Calif.--(BW HealthWire)--March 6, 2002
Beckman Coulter, Inc. (NYSE NYSE
See: New York Stock Exchange :BEC) announced today it has released a new high-sensitivity laboratory test to help physicians determine a patient's risk of coronary artery disease coronary artery disease, condition that results when the coronary arteries are narrowed or occluded, most commonly by atherosclerotic deposits of fibrous and fatty tissue. .
The test -- called CRPH -- accurately measures levels of C-reactive protein C-Reactive Protein Definition
C-reactive protein (CRP) is a protein produced by the liver and found in the blood.
C-reactive protein is not normally found in the blood of healthy people. (CRP C-reactive protein (CRP)
A protein present in blood serum in various abnormal states, like inflammation.
Mentioned in: Pelvic Inflammatory Disease
n.pr See C-reactive protein. ), a protein produced in the liver and released into the bloodstream as a result of infection or injury, such as tissue damage or inflammation caused by coronary artery disease.
"CRPH can be performed as part of a routine, physical exam to help physicians identify individuals at increased risk of coronary artery disease," said Wing Pang, vice president-director of Beckman Coulter's clinical chemistry development center. "Studies show that more traditional cardiac screening methods identify only 50 percent of individuals with a predisposition to future coronary events. But performing high-sensitivity CRP testing in conjunction with these other screening methods -- such as tests that measure cholesterol, body weight and blood pressure -- can dramatically improve a physician's ability to assess risk of cardiovascular disease Cardiovascular disease
Disease that affects the heart and blood vessels.
Mentioned in: Lipoproteins Test
cardiovascular disease ."
The new test also can aid physicians in the evaluation of stress, trauma, infection, inflammation, surgery and associated diseases.
The CRPH test is available on the company's IMMAGE(R) immunochemistry Immunochemistry
A discipline concerned both with the structure of antibody (immunoglobulin) molecules and with their ability to bind an apparently limitless number of diverse chemical structures (antigens); with the structure, organization, and rearrangement system and SYNCHRON LX(R)20 PRO chemistry analyzer.
CRPH is Beckman Coulter's second test for cardiac evaluation released in the last 12 months. In June 2001, the company launched Access(R) AccuTnI(TM), a troponin I test that aids in the diagnosis and treatment of heart attacks and cardiac muscle damage. The 12-minute test, which is one of the fastest available, is used by hospitals in routine and emergency situations. Access AccuTnI is available on Beckman Coulter's Access immunoassay Immunoassay
An assay that quantifies antigen or antibody by immunochemical means. The antigen can be a relatively simple substance such as a drug, or a complex one such as a protein or a virus. systems.
Beckman Coulter, Inc. is a global biomedical bi·o·med·i·cal
1. Of or relating to biomedicine.
2. Of, relating to, or involving biological, medical, and physical sciences. company headquartered in Fullerton, Calif. The company develops and markets instruments, chemistries, software and supplies that simplify and automate laboratory processes throughout the biomedical testing continuum. Through pioneering medical research and drug discovery, specialty testing, and patient care diagnostics, Beckman Coulter supports all phases of the battle against disease. Annual sales for the company totaled $2 billion in 2001, with 62 percent of this amount generated by recurring revenue from supplies, chemistry kits and services. For more information, visit www.beckmancoulter.com.